Phase 1/2 SLO-RP trial completed target enrollment of 48 pat…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2022 Outcomes & Outlook Report.
IN THE NEWS
05/22/2023
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023
- First oral presentation on SPVN20 in a major scientific and…
05/01/2023
Atsena Therapeutics Receives FDA Clearance of IND Application for A…
ATSN-201 leverages AAV capsid that spreads laterally beyond …
04/27/2023
SparingVision Presents Progress of its Lead Gene Therapy Program SP…
Paris, April 27, 2023 – SparingVision (“the Company”), a cli…
04/25/2023
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Ph…
ATSN-101 demonstrated clinically meaningful improvements in …
02/28/2023
RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors
Ophthalmology visionary Mark S. Blumenkranz, MD, MMS, to joi…
01/06/2023
The Retinal Degeneration Fund invests in a $78M Series B for Percei…
The investment supports the clinical development of two nove…
12/28/2022
Opus Genetics Announces Acquisition of the Rights to Two Gene Thera…
Opus to advance preclinical development programs for BEST1- …
12/01/2022
SparingVision's lead asset SPVN06 clears IND application in the US…
SparingVision set to advance into the clinic with breakthrou…
12/01/2022
Opus Genetics Receives FDA Clearance of IND Application for OPGx-00…
OPGx-001 is Opus’ first program to enter clinical evaluation…
11/10/2022
Foundation Launching its Largest Natural History Study to Date for…
Uni-Rare Study will improve clinical understanding of more I…
11/08/2022
Nacuity Pharmaceuticals Expands Board of Directors with Appointment…
Managing director of the Retinal Degeneration Fund joins boa…